PHASE I/II STUDY OF CI 980 IN ADULTS W/ NEWLY DIAGNOSED MALIGNANT GLIOMA

CI 980 在新诊断的恶性胶质瘤成人中的 I/II 期研究

• 批准号: 6263600
• 负责人: PETER PHILLIPS
• 金额: $ 2.51万
• 依托单位: UNIVERSITY OF PENNSYLVANIA
• 依托单位国家: 美国
• 财政年份: 1998
• 资助国家: 美国
• 起止时间: 1998-12-01 至 1999-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6263600
• 关键词: adult human (21+); antineoplastics; carbamates; clinical research; clinical trial phase I; drug administration rate /duration; drug adverse effect; glioma; human subject; human therapy evaluation; neoplasm /cancer chemotherapy; pyrazines; pyridine

This research study is being done to find out how well CI-980, a new investigational anti-cancer drug, works to make these tumors get smaller. To examine how well malignant gliomas respond to the drug, we will evaluate the duration of disease free progression and survival as well as the side effects of CI-980 when given continuously by vein for 72 hours every 3 weeks for 4 courses (12 weeks) in adult patients with a newly diagnosed malignant glioma.

这项研究是为了找出CI-980，一种新的实验性抗癌药物，如何使这些肿瘤变小。为了检查恶性胶质瘤对该药物的反应，我们将评估CI-980在新诊断为恶性胶质瘤的成年患者中，每3周静脉连续给予72小时，持续4个疗程（12周）时的无病进展和生存时间以及副作用。